459 related articles for article (PubMed ID: 29374053)
1. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
2. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
[TBL] [Abstract][Full Text] [Related]
3. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
5. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
[TBL] [Abstract][Full Text] [Related]
6. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
7. Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.
Long L; Zhang L; Yang Y; Zhou Y; Chen H
Immunotherapy; 2022 Apr; 14(6):419-431. PubMed ID: 35187955
[No Abstract] [Full Text] [Related]
8. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
Liao X; Zhang D
Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.
Xia C; Huang W; Chen YL; Fu HB; Tang M; Zhang TL; Li J; Lv GH; Yan YG; Ouyang ZH; Yao N; Wang C; Zou MX
Front Immunol; 2021; 12():797407. PubMed ID: 35145510
[TBL] [Abstract][Full Text] [Related]
10. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
11. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
Chen Y; Hu R; Li X; Shi Z; Tian H; Feng J; Yu S
Pathol Res Pract; 2020 Oct; 216(10):153134. PubMed ID: 32853956
[TBL] [Abstract][Full Text] [Related]
12. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
13. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
[TBL] [Abstract][Full Text] [Related]
16. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.
Zhao R; Chinai JM; Buhl S; Scandiuzzi L; Ray A; Jeon H; Ohaegbulam KC; Ghosh K; Zhao A; Scharff MD; Zang X
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9879-84. PubMed ID: 23716685
[TBL] [Abstract][Full Text] [Related]
17. HHLA2 is more significantly associated with poor prognosis in TSCC than PD-L1.
Li Y; Yang Q; Yang X; Ge J; Xu T; Liu H
J Oral Pathol Med; 2024 Feb; 53(2):159-168. PubMed ID: 38321252
[TBL] [Abstract][Full Text] [Related]
18. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
20. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
